Our journey at TrimRx began with a shared vision to help individuals embrace healthier lifestyles by merging cutting-edge telehealth innovations with effective weight loss solutions
van la Parra RFD, Deconinck C, Krug B
The recommended schedule from clinical trials is: Weeks 1-4: 2.5 mg once weekly Weeks 5-8: 5 mg once weekly Weeks 9-12: 7.5 mg once weekly Weeks 13-16: 10 mg once weekly Weeks 17-20: 12.5 mg once weekly Week 21+: 15 mg once weekly (maximum dose) Not everyone follows this exact schedule
Tirzepatide is a dual GIP/GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus in adults Common gastrointestinal adverse effects include nausea (R11.0), diarrhoea (R19.7), and vomiting (R11.1), each coded with Y42.3 Serious complications include drug-induced acute pancreatitis (K85.3), hypoglycaemia (E16.0), and acute kidney injury (N17.9), all requiring Y42.3 UK clinical coding requires the primary manifestation code followed by external cause code Y42.3 for adverse effects of antidiabetic medications All suspected adverse reactions should be reported via the MHRA Yellow Card Scheme for pharmacovigilance monitoring Table of Contents Understanding Mounjaro (Tirzepatide) and Adverse Effects Common Adverse Effects of Mounjaro and Their ICD-10 Codes Serious Adverse Effects: ICD-10 Classification and Clinical Recognition ICD-10 Coding for Mounjaro-Related Complications in UK Clinical Practice Reporting and Monitoring Adverse Effects: Yellow Card Scheme and MHRA Guidance Frequently Asked Questions Understanding Mounjaro (Tirzepatide) and Adverse Effects Mounjaro (tirzepatide) is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus in adults
Call your GP or doctor if symptoms last more than a few days or feel severe
